跳到正文
原文
STAT Pharma 医药频道· Jonathan Wosen·· 29 天前AI 评分58

AbbVie 的 lutikizumab 在化脓性汗腺炎 III 期试验中达到主要终点,但结果低于市场预期

STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

AI 导读

AbbVie 周四表示,lutikizumab 在中重度化脓性汗腺炎 III 期 Intrepid 试验中达到主要终点,但结果低于市场预期。该试验入组 1400 例患者,第 16 周时 lutikizumab 组 31.4% 的患者皮肤炎性结节和脓肿数量减少 75% 及以上,安慰剂组为 23.4%;公司称药物还达到皮肤疼痛、发作等 8 项次要终点,不良事件发生率与安慰剂组接近。

正文 · 原文

By Jonathan Wosen

Oct. 22, 2026

West Coast Biotech & Life Sciences Reporter

AbbVie reported on Thursday that an experimental therapy for hidradenitis suppurativa, a chronic skin condition, succeeded in a late-stage trial but missed market expectations, leaving experts doubtful the drug can compete with the current standard of care.

In the Phase 3 Intrepid trial, which enrolled 1,400 patients with moderate-to-severe hidradenitis suppurativa, 31.4% of participants given weekly injections of AbbVie’s therapy, lutikizumab, reported a 75% or greater reduction in the number of inflamed bumps and abscesses across their skin, compared to 23.4% of those in the placebo group after 16 weeks. This measure was the study’s primary endpoint.

The company also reported that the drug met eight secondary endpoints, including improvements in skin pain and flares. Lutikizumab was generally safe and well tolerated, with adverse event rates that were nearly identical between the placebo and treatment groups.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com